Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic ...

A transcriptome analysis of castration resistant prostate cancer metastases in a prospective cohort study reveals high expression of AKT pathway genes predictive of long term response to abiraterone ...

In metastatic prostate cancer, defects in DNA damage response genes are now established predictors of benefit to US Food and Drug Administration–approved poly (ADP-ribose) polymerase inhibitors and ...

The PARP inhibitor Lynparza improves survival and delays disease progression in men with metastatic castration-resistant prostate cancer that expresses certain gene mutations inhibiting DNA repair, a ...

Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...

"Men with these known variants should be counseled on the increased risk of prostate cancer, and I would recommend that they undergo regular PSA screening…Of course there are many other factors that ...